natgillin/translations-raw huggingface dataset:
Pain1, chest pain1, rigors1, malaise1, pyrexia
Splošne težave in spremembe na mestu aplikacije bolečina1, bolečina v prsih1, tresavica1, splošno slabo počutje1, pireksija zelo pogosti
Concentrate for solution for infusion.
Koncentrat za raztopino za infundiranje galsulfaza
Naglazyme is supplied as a concentrate for solution for infusion.
Izgled zdravila Naglazyme in vsebina pakiranja Naglazyme je na razpolago kot koncentrat za raztopino za infundiranje.
• Inflammation of the eye
• očesno vnetje
• Nausea
• srbenje
What is Taxespira and what is it used for?
Kaj je zdravilo Taxespira in za kaj ga uporabljamo
• breast cancer.
• krvni strdki.
The full EPAR and risk management plan summary for Taxespira can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske Agencije za zdravila http://www.ema.europa.eu.
• non-small-cell lung cancer.
Nedrobnocelični pljučni rak
For more information, see the summary of product characteristics.
Za nadaljnje podrobnosti prosimo, glejte povzetek glavnih značilnosti trastuzumaba.
What measures are being taken to ensure the safe and effective use of Taxespira?
POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO
By keeping the skeleton intact the cells cannot divide and they eventually die.
Če se v raztopini pojavijo kristali, raztopine ne smete več uporabiti in jo je treba zavreči.
Taxespira is used with cisplatin and 5-fluorouracil.
Cisplatin in 5-fluorouracil
The active substance docetaxel, belongs to the group of anticancer medicines known as the taxanes.
Docetaksel spada v skupino zdravil za zdravljenje raka, imenovanih taksoidi.
Taxespira is available as a concentrate for solution for infusion (drip) into a vein and is given as a onehour infusion every three weeks.
Docetaksel apliciramo v enourni infuziji vsake tri tedne.
The full EPAR for the reference medicine can also be found on the Agency's website.
To navodilo za uporabo je na voljo v vseh uradnih jezikih EU/EGP na spletni strani Evropske agencije za zdravila.
How is Taxespira used?
Kako uporabljati zdravilo Taxespira
The company provided data from the published literature on docetaxel.
Niso opazovali statistično značilnih učinkov prednizona na farmakokinetiko docetaksela.
Previously known as Docetaxel Hospira UK Limited.
IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM Hospira UK Limited
Taxespira is used with cisplatin and 5-fluorouracil (other cancer medicines);
V kombinaciji s cisplatinom in 5-fluorouracilom
Taxespira is only used when the neutrophil count (the level of a type of white blood cell in the blood) is normal (at least 1,500 cells/mm3).
Bolniki smejo docetaksel spet dobiti, šele ko se število nevtrofilcev znova zveča na vrednost ≥ 1.500 celic/mm
Taxespira is used in wards specialising in chemotherapy (using medicines to treat cancer) under the supervision of a doctor who is qualified in the use of chemotherapy.
Docetaksel se sme uporabljati le v enotah, specializiranih za citotoksično kemoterapijo in samo pod nadzorom zdravnika, izkušenega na področju onkološke kemoterapije (glejte poglavje 6.6).
Other information about Taxespira
Druga zdravila in zdravilo Taxespira
Docetaxel also affects non-cancer cells such as blood cells, which can cause side effects
Tudi deksametazon ni vplival na vezavo docetaksela na beljakovine.
For practical information about using Taxespira, patients should read the package leaflet or contact their doctor or pharmacist.
Če imate glede uporabe tega zdravila še kakšna vprašanja, vprašajte zdravnika ali bolnišničnega farmacevta.
EPAR summary for the public
Povzetek varnostnih značilnosti za vse indikacije
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
BE / LX / NL Hospira Benelux BVBA Tél/Tel: + 32 3 231 90 09
It can also be used with other cancer medicines (doxorubicin, cyclophosphamide, trastuzumab or capecitabine) in patients who have not yet received any treatment for their cancer or after other treatments have failed, depending on the type and stage of the breast cancer being treated;
Če se sočasni uporabi močnega zaviralca CYP3A4 (npr. ketokonazola, itrakonazola, klaritromicina, indinavirja, nefazodona, nelfinavirja, ritonavirja, sakvinavirja, telitromicina ali vorikonazola) ni mogoče izogniti, je potreben natančen klinični nadzor in med zdravljenjem z močnim zaviralcem CYP3A4 je lahko primerna prilagoditev odmerka docetaksela (glejte poglavje 4.4).
A risk management plan has been developed to ensure that Taxespira is used as safely as possible.
Za zmanjšanje tveganja za hematološke toksične učinke se lahko profilaktično uporabi G-CSF.
Docetaxel blocks a stage of cell division, whereby the internal ‘skeleton' is dismantled to allow the cell to divide.
In vitro docetaksel dokazano zmoti celično mikrotubulno mrežje, nujno za mitotično in interfazno celično delovanje.
For more information about treatment with Taxespira, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Če se pojavijo akutne težave s pljuči ali pride do poslabšanja simptomov (povišana telesna temperatura, težko dihanje/kratka sapa ali kašelj), takoj obvestite svojega zdravnika, medicinsko sestro ali bolnišničnega farmacevta.
An antiinflammatory medicine such as dexamethasone should also be given to the patient, starting on the day before the Taxespira infusion.
V študiji osrednjega pomena so s prvo infuzijo docetaksela začeli dan po prvem odmerku trastuzumaba.
The name of the medicine was changed to Taxespira on 12 October 2015.
To zdravilo se imenuje Taxespira.
Further information can be found in the summary of the risk management plan.
Opozorila so navedena v navodilu za uporabo.
Because Taxespira is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
V celoti rezultati študije dokazujejo ugodno razmerje koristi in tveganja TAC v primerjavi s FAC.
• head and neck cancer in patients whose cancer is locally advanced (a cancer that has grown but has not spread).
• 332 bolnikih, ki so prejemali docetaksel v kombinaciji s prednizonom ali prednizolonom(predstavljeni so klinično pomembni z zdravljenjem povezani neželeni učinki).
It can also be used with cisplatin (another cancer medicine) in patients who have not yet received any treatment for their cancer;
Zdravilo Taxespirav kombinaciji s platinskimi zdravili pri bolnikih, ki še niso bili zdravljeni s kemoterapijo
Taxespira contains the active substance docetaxel and is a ‘generic medicine'.
En ml raztopine vsebuje 20 mg docetaksela (v obliki trihidrata).
For more information on generic medicines, see the question-and-answer document here.
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom.
The dose, duration of treatment and the medicines it is used with depend on the type of cancer being treated.
Količina alkohola v tem zdravilu lahko spremeni učinke drugih zdravil.
This summary was last updated in 01-2016.
Še prisotno amenorejo so med spremljanjem, v študiji TAX316, zabeležili pri 121 od 202 bolnicah, ki so imele amenorejo ob koncu kemoterapije.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Taxespira, including the appropriate precautions to be followed by healthcare professionals and patients.
Za te reakcije je bil značilen izpuščaj, vključno z lokaliziranimi erupcijami, predvsem na dlaneh in stopalih (vključno z resnim roka/noga sindromom), pa tudi na rokah, obrazu in prsnem košu; pogosto jih je spremljalo srbenje.
Taxespira is used with prednisone or prednisolone (anti-inflammatory medicines);
Zdravilo Taxespiraje v kombinaciji s prednizonom ali prednizolonom indicirano za zdravljenje bolnikov z metastatskim hormonsko neodzivnim rakom prostate.
The company also showed that Taxespira solution for infusion has comparable quality to that of Taxotere.
Za kombinacijo docetaksel/karboplatin v primerjavi z referenčno terapevtsko kombinacijo VCis ni bilo mogoče dokazati niti enakovredne niti neinferiorne učinkovitosti.
No additional studies in humans were needed as Taxespira is a generic medicine that is given by infusion and contains the same active substance as Taxotere.
Omejeni podatki iz ene same nekontrolirane študije so nakazovali interakcijo med docetakselom in karboplatinom.
The European Commission granted a marketing authorisation valid throughout the European Union for Docetaxel Hospira UK Limited on 28 August 2015.
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 28 avgust 2015
Date of first authorisation: 04 December 1998 Date of latest renewal: 21 May 2008
Datum prve odobritve: 04. december 1998 Datum zadnjega podaljšanja: 21. maj 2008
Not known (frequency cannot be estimated from the available data)
Pogostnost neznana (je ni mogoče oceniti iz razpoložljivih podatkov)
Population/Visit
Skupina/obisk
Each bottle contains 250 capsules.
Vsaka steklenica vsebuje 250 kapsul.
• The patch can be used in everyday situations, including bathing and during hot weather.
• Obliž je mogoče uporabljati v vsakdanjih situacijah, tudi med kopanjem in v vročem vremenu.
During the course of the treatment your doctor may adjust the dose to suit your individual needs.
Med potekom zdravljenja vam lahko zdravnik prilagodi odmerek, da bo ustrezal vašim osebnim potrebam.
The patient reminder card should contain the following key messages:
Opozorilna kartica za bolnika mora vsebovati naslednja ključna sporočila:
Frequency categories are defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Kategorije pogostnosti so opredeljene z naslednjim dogovorom: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
• Pull the plunger upwards until it reaches the right mark for the dose that your doctor has prescribed.
• Bat vlecite navzgor, dokler ne doseže prave oznake za odmerek, ki vam ga je prepisal zdravnik.
• To benefit from your medicine, take it every day.
• Da vam bo zdravilo pomagalo, ga morate jemati vsak dan.
• Seeing things that are not really there (hallucinations)
• vidna zaznava nečesa, česar v resnici ni tam (halucinacije)
Prometax can be used with food, drink and alcohol.
Zdravilo Prometax lahko uporabljate skupaj s hrano, pijačo in alkoholom.
However, Prometax may be used in this patient population and close monitoring is necessary.
Vendar se zdravilo Prometax v tej populaciji bolnikov lahko uporabi in potrebno je natančno spremljanje.
They are packed in blisters available in three different pack sizes (28, 56 or 112 capsules) and plastic bottles of 250 capsules, but these may not all be available in your country.
Pakirane so v pretisnih omotih, ki so na voljo v treh različnih velikostih pakiranj (28, 56 ali 112 kapsul) in v plastičnih steklenicah s po 250 kapsulami, vendar morda v vaši državi niso na voljo vsa navedena pakiranja.
• Bathing, swimming or showering should not affect the patch.
- Kopanje, plavanje in prhanje ne bi smeli vplivati na obliž.
Source: Study D2340-Table 11-6 and Table 11-7
Vir: Študija D2340-preglednici 11-6 in 11-7
• Urinary incontinence (inability to retain adequate urine)
• urinska inkontinenca (nezmožnost zadrževanja urina)
You should only open the sachet when you are ready to apply the patch.
Vrečko odprite šele, ko boste pripravljeni na nameščanje obliža.
• The previous day's patch must be removed before applying a new one every day (see section 4.9).
• Vsak dan je treba pred nameščanjem novega obliža odstraniti obliž predhodnega dne (glejte poglavje 4.9).
If you find you have forgotten to take your dose of Prometax, wait and take the next dose at the usual time.
Če ugotovite, da ste pozabili vzeti odmerek zdravila Prometax, počakajte in ob običajnem času vzemite naslednji odmerek.
• Hyperactivity (high level of activity, restlessness)
• hiperaktivnost (povečana stopnja aktivnosti, nemir)
At least 4 points improvement on ADASCog with no worsening on CIBIC-Plus and PDS *p<0.05, **p<0.01, ***p<0.001
Izboljšanje za vsaj 4 točke pri ADAS-Cog brez poslabšanja pri CIBIC-Plus in PDS *p<0,05, **p<0,01, ***p<0,001
Skin application site reactions
Reakcije na mestu apliciranja na kožo
Maintenance treatment can be continued for as long as a therapeutic benefit for the patient exists.
Vzdrževalno zdravljenje lahko nadaljujemo, dokler ima bolnik od njega terapevtske koristi.
After using the syringe
Po uporabi brizge
The MAH shall ensure that, following discussions and agreement with the National Competent Authorities in each Member State where Prometax patch is marketed, all physicians who are expected to prescribe Prometax patch are provided with an information pack containing the following elements:
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da bodo po razpravi in pridobitvi soglasja nacionalnega pristojnega organa v vsaki državi članici, kjer je zdravilo Prometax obliž dostopno na trgu, vsi zdravniki, za katere se pričakuje, da bodo predpisovali zdravilo Prometax obliž, prejeli komplet navodil, ki bo vseboval sledeče:
- Each patch is sealed in its own protective sachet.
Vsak obliž je zaprt v svojo zaščitno vrečko.
Can you wear your Prometax transdermal patch when you are bathing, swimming, or in the sun?
Se sme transdermalni obliž Prometax nositi med kopanjem in plavanjem ter na soncu?
Clear, yellow solution.
Bistra, rumena raztopina.
Your doctor will tell you which Prometax transdermal patch is most suitable for you.
Zdravnik vam bo povedal, kateri transdermalni obliž Prometax je za vas najbolj primeren.
Hypersensitivity to the active substance rivastigmine, to other carbamate derivatives or to any of the excipients listed in section 6.1.
Preobčutljivost na učinkovino rivastigmin, druge derivate karbamata ali katero koli pomožno snov, navedeno v poglavju 6.1.
Each box contains 28, 56 or
Vsaka škatla vsebuje 28, 56 ali 112 kapsul.
Rivastigmine is weakly bound to plasma proteins (approximately 40%).
Rivastigmin se šibko veže na beljakovine v plazmi (približno 40 %).
Parkinson's disease (worsening)
Parkinsonova bolezen (poslabšanje)
Put the sticky side of the patch on the upper or lower back, upper arm or chest and then peel off the second side of the protective liner.
Lepljivo stran obliža položite na zgornji ali spodnji del hrbta, nadlaket ali na prsi in nato odstranite drugo polovico zaščitne plasti.
30 transdermal patches.
30 transdermalnih obližev.
Multipack: 60 (2 packs of 30) transdermal patches Multipack: 90 (3 packs of 30) transdermal patches
Skupno pakiranje: 60 (2 pakiranji po 30) transdermalnih obližev Skupno pakiranje: 90 (3 pakiranja po 30) transdermalnih obližev
You may wish to experiment with different locations when applying a new patch, to find ones that are most comfortable for you and where clothing will not rub on the patch.
Ko nameščate nove obliže, lahko preskušate različna mesta na koži, da bi ugotovili, katero vam je najbolj udobno in kje oblačila najmanj drgnejo kožo.
Prometax should not be given at the same time as other medicines with similar effects to Prometax.
Zdravila Prometax ne smete jemati sočasno z drugimi zdravili, ki imajo podobne učinke kot zdravilo Prometax.
• Feeling tired or weak
• občutek utrujenosti ali šibkosti
• Your doctor will slowly increase your dose depending on how you respond to treatment.
• Zdravnik vam bo odmerek počasi zviševal glede na vaš odziv na zdravljenje.
Absolute bioavailability after a 3 mg dose is about 36%  13%.
Absolutna biološka uporabnost po odmerku 3 mg je okrog 36 %  13 %.
Efficacy has been established by the use of two independent scales which were assessed at regular intervals during a 6-month treatment period as shown in Table 5 below: the ADAS-Cog, a measure of cognition, and the global measure ADCS-CGIC (Alzheimer's Disease Cooperative StudyClinician's Global Impression of Change).
Učinkovitost so dokazali z uporabo dveh neodvisnih lestvic, s katerima so bolnike ocenjevali v rednih presledkih med 6-mesečnim obdobjem zdravljenja, kot kaže preglednica 5 spodaj: ADAS-Cog, merilo kognitivne zmogljivosti, in globalno merilo ADCS-CGIC (Alzheimer's Disease Cooperative Study-Clinician's Global Impression of Change /Kooperativna študija Alzheimerjeve bolezni-globalni klinični vtis sprememb).
The incidence of application site skin reactions leading to discontinuation was higher in the Asian population with 4.9% and 8.4% in the Chinese and Japanese population respectively.
V azijski populaciji pa je bila pogostnost reakcij na mestu aplikacije, zaradi katerih je bilo treba zdravljenje prekiniti, večja - v kitajski populaciji je znašala 4,9 %, v japonski populaciji pa 8,4 %.
Based on CMH test (van Elteren test) blocking for country.
Na podlagi testa CMH (van Elternovega testa) analize po kategorijah za posamezne države.
Rivastigmine transdermal patches were not phototoxic and considered to be a non-sensitiser.
Transdermalni obliži z rivastigminom niso bili fototoksični in veljajo za obliže, ki ne povzročajo preobčutljivosti.
Uncommon (may affect up to 1 in 100 people) • Hyperactivity (high level of activity, restlessness)
Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov) • hiperaktivnost (povečana stopnja aktivnosti, nemir)
Every 24 hours take off the previous patch before putting ONE new patch on to ONLY ONE of the following possible locations.
Vsakih 24 ur najprej odstranite prešnji obliž, nato pa namestite EN nov obliž na SAMO ENO od naslednjih možnih mest.
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX)
VMESNA ŠKATLICA SKUPNEGA PAKIRANJA (BREZ "BLUE BOX" PODATKOV)
Prometax transdermal patches may cause fainting or severe confusion.
Transdermalni obliži Prometax lahko povzročajo omedlevico ali hudo zmedenost.
These events led to the discontinuation of rivastigmine in some cases (e.g. discontinuations due to tremor 1.7% on rivastigmine vs 0% on placebo).
Zaradi teh težav so v nekaterih primerih prekinili zdravljenje z rivastigminom (npr. z rivastigminom 1,7 % prekinitev zaradi tremorja v primerjavi z 0 % pri placebu).
• Tell your caregiver that you are taking Prometax.
• Povejte svojemu negovalcu, da jemljete zdravilo Prometax.
• The patch should not be cut into pieces.
• Obliža se ne sme rezati na manjše dele.
In view of its pharmacodynamic effects and possible additive effects, rivastigmine should not be given concomitantly with other cholinomimetic substances.
Zaradi njegovih farmakodinamičnih učinkov in možnosti aditivnega delovanja se rivastigmina ne sme uporabljati skupaj z drugimi holinomimetičnimi snovmi.
• Severe confusion
• huda zmedenost
Such events appeared to occur particularly after dose increments or high doses of rivastigmine.
Do takih dogodkov je prišlo predvsem po povečevanju odmerka ali uporabi velikih odmerkov rivastigmina.
It was rated as severe in ≤2.2% of patients in these studies and in ≤3.7% of patients treated with Prometax transdermal patches in a Japanese study.
V teh študijah so vnetje ocenili kot hudo pri ≤2,2 % bolnikov, v japonski študiji pa pri ≤3,7 % bolnikov, ki so se zdravili s transdermalnimi obliži Prometax.
In other cases, Prometax has been discontinued (see section 4.8).
V drugih primerih so zdravilo Prometax ukinili (glejte poglavje 4.8).
• Stiff arms or legs
• okorele roke ali noge
• Allergic reaction where the patch was used, such as blisters or skin inflammation If you get any of these side effects, contact your doctor as you may need medical assistance.
• alergijske reakcije na mestu uporabe obliža, kot je pojav mehurjev ali vnete kože Če se pojavijo takšni neželeni učinki, obvestite svojega zdravnika, ker boste morda potrebovali zdravniško pomoč.
N is the number of patients with an assessment at baseline (last assessment in the initial openlabel phase) and with at least 1 post-baseline assessment (for the LOCF).
N je število bolnikov, ki so opravili izhodiščno ocenjevanje (zadnje ocenjevanje v fazi odprtega zdravljenja) in še najmanj 1 ocenjevanje za tem (za vrednost, ki jo je mogoče uporabiti pri metodi LOCF)
Based on population analysis, creatinine clearance did not show any clear effect on steady state concentrations of rivastigmine or its metabolite.
Po podatkih populacijske analize očistek kreatinina ni kazal jasnega učinka na koncentracije rivastigmina ali njegovih presnovkov v stanju dinamičnega ravnovesja.
Other medicines and Prometax
Druga zdravila in zdravilo Prometax
• to patients predisposed to urinary obstruction and seizures because cholinomimetics may induce or exacerbate these diseases;
• bolnikom, ki so nagnjeni k zapori sečnih izvodil in k epileptičnim napadom, ker holinomimetiki lahko sprožijo te bolezni ali njihovo poslabšanje;
What Prometax is and what it is used for
Kaj je zdravilo Prometax in za kaj ga uporabljamo
The capsules and oral solution can also be used for the treatment of dementia in adult patients with Parkinson's disease.
Kapsule in peroralno raztopino lahko uporabljamo tudi za zdravljenje demence pri odraslih bolnikih s Parkinsonovo boleznijo.
Your doctor will tell you what dose of Prometax to take.
Zdravnik vam bo povedal, kakšen odmerek zdravila Prometax morate jemati.
• Apply ONE patch per day to ONLY ONE of the possible locations shown in the following diagrams: left upper arm or right upper arm left upper chest or right upper chest (avoid breast) left upper back or right upper back left lower back or right lower back
• Namestite EN obliž na dan na SAMO ENO od možnih mest, ki so prikazana na naslednji skici: levi nadlaket ali desni nadlaket levi zgornji del prsi ali desni zgornji del prsi (ne na dojko) levi zgornji del hrbta ali desni zgornji del hrbta levi spodnji del hrbta ali desni spodnji del hrbta
• Trembling or feeling confused
• tresenje ali občutek zmedenosti
• The patch should be replaced by a new one after 24 hours.
• Obliž je treba po 24 urah zamenjati z novim.
• After removing a patch, fold it in half with the sticky sides on the inside and press them together.
• Po odstranitvi obliža s kože ga prepognite na pol z lepljivo stranjo navznoter in stisnite.
Only one patch should be worn at a time (see section 4.9).
Nameščen sme biti samo en obliž naenkrat (glejte poglavje 4.9).
If you have not taken Prometax for more than three days, do not take the next dose until you have talked to your doctor.
Če zdravila Prometax niste jemali že več kot tri dni, ne vzemite naslednjega odmerka, dokler se ne pogovorite s svojim zdravnikom.
Misuse of the medicinal product and dosing errors with Prometax transdermal patch have resulted in serious adverse reactions; some cases have required hospitalisation, and rarely led to death (see section 4.9).
Zaradi nepravilne uporabe in napak pri odmerjanju zdravila Prometax je prišlo do resnih neželenih učinkov; v nekaterih primerih je bila potrebna hospitalizacija, redko pa je prišlo do smrtnega izida (glejte poglavje 4.9).
• to patients with a history of asthma or obstructive pulmonary disease.
• bolnikom z anamnezo astme ali obstruktivne pljučne bolezni.
Table 3 lists the number and percentage of patients from the specific 24-week clinical study conducted with Prometax in patients with dementia associated with Parkinson's disease with pre-defined adverse events that may reflect worsening of parkinsonian symptoms.
Preglednica 3 navaja število in delež bolnikov iz specifične 24-tedenske klinične študije z zdravilom Prometax pri bolnikih z demenco, povezano s Parkinsonovo boleznijo, z vnaprej opredeljenimi neželenimi dogodki, ki lahko odražajo poslabšanje simptomov Parkinsonove bolezni.
• Fast or uneven heartbeat
• hitro ali neenakomerno bitje srca
How to apply your Prometax transdermal patch Prometax patches are thin, opaque, plastic patches that stick to the skin.
Kako namestiti transdermalni obliž Prometax Obliži Prometax so tanki neprozorni plastični obliži, ki jih prilepite na kožo.
times the maximum clinical exposure.
4-krat večjem od največje klinične izpostavljenosti.